arrow
S

Simon Peter Gampenrieder

paracelsus medical university
H指数:20
被引数:1,686

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Characterization, immune cell phenotyping and differential gene expression analysis of brain metastases and primary breast cancer samples

脑转移和原发乳腺癌样本的特性表征、免疫细胞分型及差异基因表达分析

2026-03-290
OAAI
Different types of electrostimulation target specific impaired sensory and motor functions in chemotherapy-induced peripheral neuropathy: a secondary analysis of a controlled trial

不同类型的电刺激针对化疗诱导的周围神经病变中的特定受损感觉和运动功能:一项对照试验的二次分析

2026-03-040
OAAI
Enfortumab vedotin plus pembrolizumab in treatment-naïve metastatic urothelial carcinoma patients: An Austrian real-world analysis

恩福妥单抗 vedotin 联合帕博利珠单抗治疗初治转移性尿路上皮癌患者:一项奥地利真实世界分析

2025-10-220
OAAI
Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trials
BREAST
IF7.9
2025-04-010
OAAI
Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting? (Jan, 10.1007/s10549-023-07186-6, 2024)
2024-05-050
OAAI
Change of first-line treatment pattern in metastatic luminal breast cancer: Results from the Austrian AGMT_MBC-Registry
2024-05-020
PRE
Pathological response according to early metabolic remission in an interim FDG-PET scan and to tumor infiltrating lymphocytes - A secondary analysis of the phase II trial ABCSG 52/ATHENE investigating atezolizumab in early HER2+BC
2024-05-020
PRE
Drop-out rates from line to line of treatment in metastatic breast cancer (MBC): Results from the Austrian AGMT_MBC-Registry
2024-05-020
PRE
Prognosis and treatment landscape of HER2-positive metastatic breast cancer (MBC) before the availability of tucatinib and trastuzumab-deruxtecan: Results from the Austrian AGMT_MBC-Registry
2023-03-010
PRE
De-escalation of bone-targeted treatment: Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12
2023-03-010
PRE
Number of involved organs at baseline is prognostic for overall survival in patients with metastatic breast cancer: Results from the AGMT_MBC-Registry
2023-03-010
PRE
Influence of HER2 expression on prognosis in metastatic triple-negative breast cancerdresults from an international, multicenter analysis coordinated by the AGMT Study Group
2023-02-0110
OAAI
Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12
2023-02-014
PRE
Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force
2022-06-015
OAAI